Advanced T cell therapy : current research
This research team belongs to the UMR 1015 - Tumor immunology and immunotherapies
We develop genome editing approaches derived from CRISPR-cas9 technology (inactivation, activation, base editing, genome-wide) to understand the biology of T cells but also improve the composition, functionality, and persistence of therapeutic cell products, CAR-T, and TILs (tumor-infiltrating lymphocytes).
Our team was the first in Europe to establish CRISPR-Cas9 screening in vivo in primary T cells, developing a functional pipeline for the unbiased and systematic characterization of T cell limiting factors in complex immunosuppressive environments. The team now integrates additional developments in synthetic biology using genome-wide CRISPR activation modification, editing of tumour-infiltrating lymphocytes, CAR combinatorial therapies and modulating epigenetic regulators of the antitumor immune response in vivo.
